Fresenius to cut margin on $3bn lev loan
Fresenius, the German medical firm, wants to renegotiate a $2.95bn leveraged loan taken out in 2008 as it tries to cut costs, showing that the strongest speculative grade borrowers are growing in confidence and becoming more aggressive with lenders over pricing.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
